Mode
Text Size
Log in / Sign up
N/A Completed N=15 Randomized Double-blind Treatment

Clinical Evaluation of Two Monthly Contact Lenses

Source: ClinicalTrials.gov NCT03459131 ↗
Enrolled (actual)
15
Serious AEs
0.0%
Results posted
Mar 2019
Primary outcomePrimary: Subjective Rating of Overall Vision — 8.6; 8.6 units on a scale

Summary

The purpose of this study is to explore overall vision with BIOFINITY® ENERGYS™ contact lenses as compared to BIOFINITY® contact lenses after one week of wear.

Outcome Measures

OutcomeResultp-value
PRIMARY
Subjective Rating of Overall Vision
8.6; 8.6
SECONDARY
Over-refraction
3; 0; 26; 24; 1; 6

Eligibility Criteria

Inclusion Criteria

  • Able to understand and sign an approved informed consent form (ICF);
  • Successful wear of BIOFINITY® (spherical) (or private label) contact lenses in both eyes for a minimum of 5 days per week and 8 hours per day during the past 3 months;
  • Best-corrected visual acuity (BCVA) 20/25 or better in each eye;
  • Possess spectacles that provide a corrected visual acuity of 20/40 or better in both eyes (OU) and be willing to wear them (as needed);
  • Currently using digital devices (computer, tablet, and/or smart phone) for a minimum of 5 days per week and 4 hours per day;
  • Other protocol-specified inclusion criteria may apply.

Exclusion Criteria

  • Any anterior segment infection, inflammation, abnormality or disease that contraindicates contact lens wear;
  • Any use of systemic or ocular medications for which contact lens wear could be contraindicated;
  • Refractive, ocular, or intraocular surgery, as specified in the protocol;
  • Current or history of eye injury or disorders, as specified in the protocol;
  • Current or history of intolerance, hypersensitivity or allergy to any component of the study products;
  • Habitual contact lens wear in an extended wear modality (routinely sleeping in lenses for at least 1 night per week) over the last 3 months prior to enrollment;
  • Use of topical ocular medications that would require instillation during contact lens wear;
  • Other protocol-specified exclusion criteria may apply.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03459131). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search